NCT00891748View on ClinicalTrials.gov

Safety Study on AdCD40L Gene Therapy for Bladder Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

October 31, 2009

Study Completion Date

October 31, 2009

Conditions
Bladder Cancer
Interventions
GENETIC

AdCD40L

Adenovirus vector serotype 5, E1/E3 deletion with human CD40L gene driven by RSV promoter

Trial Locations (1)

75185

Uppsala University Hospital, Uppsala

All Listed Sponsors
collaborator

Uppsala University Hospital

OTHER

lead

Uppsala University

OTHER

NCT00891748 - Safety Study on AdCD40L Gene Therapy for Bladder Cancer | Biotech Hunter | Biotech Hunter